Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
暂无分享,去创建一个
[1] P. Hegde,et al. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] D. Schrump,et al. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. , 2018, Human pathology.
[3] E. Felley-Bosco,et al. The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma , 2017, Oncoimmunology.
[4] J. Aerts,et al. Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.
[5] E. Smits,et al. CD56 in the Immune System: More Than a Marker for Cytotoxicity? , 2017, Front. Immunol..
[6] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[7] N. Hens,et al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma , 2017, Oncoimmunology.
[8] S. Sakaguchi,et al. Regulatory T cells in cancer immunotherapy , 2016, Cell Research.
[9] P. Jänne,et al. Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors , 2016, Cancer Immunology Research.
[10] S. Steinberg,et al. Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD‐L1 and the PD‐L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD‐L1 Antibody Avelumab , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] C. Ries,et al. Macrophage Susceptibility to Emactuzumab (RG7155) Treatment , 2016, Molecular Cancer Therapeutics.
[12] N. Le Stang,et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. , 2016, Human pathology.
[13] E. Felip,et al. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). , 2016, Lung cancer.
[14] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[15] Daniela Massi,et al. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. , 2016, Critical reviews in oncology/hematology.
[16] A. Nicholson,et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] E. Puré,et al. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. , 2015, Cancer research.
[18] H. Hoogsteden,et al. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. , 2015, Lung cancer.
[19] David R. Jones,et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers , 2015, Oncoimmunology.
[20] E. Felip,et al. Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) , 2015, PloS one.
[21] H. Hoogsteden,et al. Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma , 2014, PloS one.
[22] J. Aerts,et al. Immunomodulation in cancer. , 2014, Current opinion in pharmacology.
[23] A. Mansfield,et al. B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] B. Fox,et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.
[25] C. Verschraegen,et al. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. , 2013, The American journal of pathology.
[26] M. Neurath,et al. The emerging role of T cell cytokines in non-small cell lung cancer. , 2012, Cytokine & growth factor reviews.
[27] S. Rosenberg,et al. Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes , 2012, Journal of immunotherapy.
[28] D. Sugarbaker,et al. Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation , 2012, Clinical Cancer Research.
[29] A. Gazdar,et al. Malignant mesothelioma: Facts, Myths, and Hypotheses , 2012, Journal of cellular physiology.
[30] D. Sugarbaker,et al. Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma , 2011, Cancer.
[31] M. Sadelain,et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma , 2011, Cancer Immunology, Immunotherapy.
[32] Wei Wang,et al. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. , 2011, The American journal of pathology.
[33] C. Sima,et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients , 2011, Cancer Immunology, Immunotherapy.
[34] H. Hoogsteden,et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function , 2010, BMC Cancer.
[35] M. Nimwegen,et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma , 2010, British Journal of Cancer.
[36] M. Nishimura,et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection , 2010, Cancer Immunology, Immunotherapy.
[37] H. Hoogsteden,et al. Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity , 2010, Journal of biomedicine & biotechnology.
[38] P. Allavena,et al. Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.
[39] S. Mocellin,et al. IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients1 , 2009, The Journal of Immunology.
[40] A. Darabi,et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy , 2009, Cancer Immunology, Immunotherapy.
[41] W. Paul,et al. CD4 T cells: fates, functions, and faults. , 2008, Blood.
[42] M. Tsao,et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. , 2008, The Journal of thoracic and cardiovascular surgery.
[43] H. Hammad,et al. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.
[44] Terry J. Smith,et al. More Than Structural Cells, Fibroblasts Create and Orchestrate the Tumor Microenvironment , 2006, Immunological investigations.
[45] C. June,et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma , 2005, Cancer biology & therapy.
[46] E. van Marck. Pathology of malignant mesothelioma. , 2004, Lung cancer.
[47] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[49] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[50] W. Wallace,et al. No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[51] P. Schlag,et al. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.
[52] W. Richards,et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.
[53] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[54] R. Ball,et al. IMMUNOREACTIVITY FOR HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND ITS RECEPTOR, met, IN HUMAN LUNG CARCINOMAS AND MALIGNANT MESOTHELIOMAS , 1996, The Journal of pathology.
[55] I. Webster,et al. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.